

VOLUME 283 (2008) PAGES 15807–15815

DOI 10.1074/jbc.A116.708933

**Involvement of hypoxia-inducing factor-1 $\alpha$ -dependent plasminogen activator inhibitor-1 up-regulation in Cyr61/CCN1-induced gastric cancer cell invasion.**

Ming-Tsan Lin, I-Hsin Kuo, Cheng-Chi Chang, Chia-Yu Chu, Hsing-Yu Chen, Been-Ren Lin, Munisamy Sureshbabu, Hou-Jung Shih, and Min-Liang Kuo

This article has been withdrawn by authors Ming-Tsan Lin, I-Hsin Kuo, Cheng-Chi Chang, Chia-Yu Chu, Been-Ren Lin, and Min-Liang Kuo. The same images were used to represent different experimental conditions. In Fig. 1A, lanes 2 and 4 of the HIF-1 $\alpha$  DNA gel were duplicated. The HIF-1 $\alpha$  DNA gel from Fig. 1A was reused in Fig. 1E in the HIF-1 $\alpha$  rCyr61 panel. The GAPDH DNA gel from Fig. 1A was reused in Fig. 1E as GAPDH rCyr61 and IGF-1 panels, Fig. 5A as GAPDH, and Fig. 6B as input, left panel. The HIF-1 $\beta$  immunoblot from Fig. 1A was reused in Fig. 1B as HIF-1 $\beta$ , AGS and TSGH panels, Fig. 1D as HIF-1 $\beta$ , N87 panel, Fig. 1F as HIF-1 $\beta$ , rCyr61 panel, and Fig. 3D as HIF-1 $\beta$ . The tubulin immunoblot from Fig. 1A was reused in Fig. 5B as tubulin, lower panel, and reused in Fig. 5E as tubulin, left panel. In Fig. 1C, lanes 1 and 2 of the HIF-1 $\alpha$  immunoblot were reused in lanes 5 and 6. In Fig. 1D, the HIF-1 $\alpha$  immunoblot from the N87 panel was reused in Fig. 1F in the HIF-1 $\alpha$  IGF-1 panel. In Fig. 1E, lanes 2 and 3 of the HIF-1 $\alpha$  DNA gel from the rCyr61 panel were duplicated in lanes 5 and 6 of the same panel. Also in Fig. 1E, the HIF-1 $\alpha$  DNA gel from the CoCl<sub>2</sub> panel was reused in the IGF-1 panel as HIF-1 $\alpha$ . In Fig. 1F, lanes 4 and 5 were duplicated in the HIF-1 $\beta$  immunoblot from the CoCl<sub>2</sub> panel. The HIF-1 $\beta$  immunoblot from the IGF-1 panel in Fig. 1F was reused in Fig. 3A as tubulin. In Fig. 1G, lanes 1 and 2 of the tubulin immunoblot, left panel, was reused in lanes 3 and 4 of the same panel. In Fig. 2A, lanes 2 and 4 of the HIF-1 $\alpha$  immunoblot and lanes 3 and 4 of the HIF-1 $\beta$  immunoblot from the CoCl<sub>2</sub> panel were duplicated. In Fig. 2C, lanes 1 and 2 of the HIF-1 $\beta$  immunoblot were duplicated in lanes 4 and 5, lanes 7 and 8, lanes 9 and 10, and lanes 11 and 12. Also, in the same panel, lanes 3 and 6 were duplicated. In Fig. 3A, lanes 4 and 5 of the HIF-1 $\beta$  immunoblot were duplicated. Also in the same figure, lane 1 of the p-AKT immunoblot was duplicated in lanes 3 and 5, and lane 2 of the AKT immunoblot was duplicated in lane 5. The AKT immunoblot from Fig. 3A was also reused in Fig. 3D as 4E-BP1. In Fig. 3B, lane 1 of the p-AKT immunoblot was reused in lanes 5 and 6, and lane 1 of the AKT immunoblot was reused in lane 6. In Fig. 3D, lane 1 of the HIF-1 $\alpha$  immunoblot was reused in lane 6, and lane 1 of the p-p70S6K immunoblot was reused in lane 5. The graphs in Fig. 4A were duplicated. In Fig. 5A, lane 1 of the c-MET DNA gel was reused in lanes 5 and 6, and lane 2 of the same gel was reused in lane 4. Also in Fig. 5A, lanes 1–3 of the AMF gel were reused in lanes 4–6. In Fig. 5C, lane 1 of the PAI-1 DNA gel was reused in lane 2, and lane 1 of the GAPDH DNA gel was reused in lane 2. In Fig. 6A, lanes 1 and 4 of the tubulin immunoblot were duplicated. Lane 2 of the PAI-1 DNA gel from Fig. 6B, left panel, was reused in lanes 2 and 3 of the PAI-1 DNA gel, right panel. In Fig. 6B, lanes 1 and 4 of the input DNA gel, right panel, were duplicated.

Authors are urged to introduce these corrections into any reprints they distribute. Secondary (abstract) services are urged to carry notice of these corrections as prominently as they carried the original abstracts.